La Jolla Pharma (LJPC) 18.79 $LJPC
La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Business Wire - Mon Feb 09, 7:01AM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assesment (SPA) for its Phase 3 clinical trial of LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). In accordance with the SPA, the primary efficacy endpoint for this Phase 3 registration trial will be increase in blood pressure. La Jolla plans to initiate this multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial pursuant to the approved SPA in the first quarter of 2015.
LJPC: 18.79 (unch)
La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 04, 7:00AM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 17th Annual BIO CEO & Investor Conference taking place February 9-10 in New York City.
LJPC: 18.79 (unch)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Galectin up on Phase 1 results in NASH
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 7:50AM CST
GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
La Jolla Pharmaceutical (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:19AM CST
La Jolla Pharmaceutical (LJPC) Shares March Higher, Can It Continue?
LJPC: 18.79 (unch)
Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
Business Wire - Mon Dec 29, 1:40PM CST
Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast(TM) (NK-92(TM)), a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D. to the Company's Board of Directors. Mr. Rosen is President of Heron Therapeutics (NASDAQ:HRTX) and Dr. Ji is co-founder, President and CEO of Sorrento Therapeutics, Inc. (NASDAQ:SRNE).
HRTX: 10.29 (+0.39), LJPC: 18.79 (unch), SRNE: 11.41 (+0.56)
Weakness Seen in La Jolla Pharmaceutical (LJPC): Stock Tumbles 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:41AM CST
La Jolla Pharmaceutical aw a big move last session, as the company’s shares fell by nearly 18% which reversed the trend for the company.
LJPC: 18.79 (unch), ARQL: 1.35 (+0.04)
Insider Buys And Sells: American Homes 4 Rent, Western Gas Partners
Asif Suria - at Seeking Alpha - Mon Dec 22, 3:50PM CST
Welcome to edition 235 of Insider Weekends. The prolific buying by insiders of energy companies lost some steam last week even as oil and energy stocks rebounded sharply along with the rest of the market. With the S&P 500 closing less than 5...
RH: 86.77 (-1.55), AMH: 16.58 (-0.10), VRTX: 113.66 (+4.03), CODI: 16.61 (+0.03), RES: 13.36 (+0.93), LJPC: 18.79 (unch), ICE: 233.22 (-1.21), WES: 71.50 (+0.18), ENH: 64.63 (+0.15), GHC: 976.65 (+15.51)
The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 6:37AM CST
LJPC: 18.79 (unch), GALT: 3.84 (+0.16)
La Jolla up on angiotensin IP deal
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:58AM CST
LJPC: 18.79 (unch)
How La Jolla Pharmaceutical (LJPC) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:43AM CST
La Jolla Pharmaceutical is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 72
LJPC: 18.79 (unch)
InsiderInsights.com Daily Round Up 12/15/14: NS, FCX, LJPC, OAS
InsiderInsights - at Seeking Alpha - Tue Dec 16, 2:28AM CST
VR: 42.10 (+0.07), GMCR: 118.53 (+0.56), LJPC: 18.79 (unch), FCX: 20.29 (+0.82), NS: 61.94 (-0.06), OSIS: 71.63 (-0.04), SNI: 73.00 (+0.39), GOOG: 549.01 (+6.08), HAIN: 59.48 (+0.45), WIW: 11.29 (unch), IDRA: 4.10 (-0.14), VRNS: 37.34 (+0.60), WRLD: 78.79 (-0.21), SNPS: 44.90 (+0.03), AI: 25.03 (-0.03), JGW: 10.70 (-0.16), OAS: 16.84 (-0.03), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59)
La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 7.29 (-0.06), LCI: 57.78 (-0.91), LJPC: 18.79 (unch), IG: 10.57 (-0.12)
La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement
Business Wire - Tue Dec 09, 3:01PM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and the George Washington University (GW), today announced that La Jolla and GW have entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. La Jolla plans to initiate a phase 3 registration program of LJPC-501, La Jolla's proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH) in the first quarter of 2015.
LJPC: 18.79 (unch)
LaJolla down on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST
LJPC: 18.79 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 11:48AM CST
IMDZ: 25.34 (+1.20), VTNR: 3.55 (+0.25), CYBR: 52.52 (+6.83), LJPC: 18.79 (unch), ZAZA: 2.17 (+0.08), XPLR: 7.00 (+0.26), FUEL: 14.30 (+0.65), NADL: 2.10 (-0.02), DWA: 20.72 (+0.34), CZR: 10.78 (+0.18), RCAP: 10.28 (+0.28), AMTX: 4.52 (+0.13), FLML: 14.15 (+0.15), AMOT: 22.39 (-0.13), RVNC: 16.84 (+0.27), LOCM: 0.65 (-0.03), JGW: 10.70 (-0.16), ICLD: 2.87 (+0.11), VPCO: 1.02 (+0.01), CSH: 20.53 (-0.31)
La Jolla Pharma -12.5% AH after Q3 report, Phase 2 study results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:00PM CST
LJPC: 18.79 (unch)
La Jolla Pharmaceutical posts 3Q loss
Automated Insights - Wed Nov 12, 4:06PM CST
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Wednesday reported a loss of $5.1 million, or 37 cents per share, in its third quarter.
LJPC: 18.79 (unch)
La Jolla Pharmaceutical misses by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:39PM CST
LJPC: 18.79 (unch)
La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Business Wire - Mon Feb 09, 7:01AM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assesment (SPA) for its Phase 3 clinical trial of LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). In accordance with the SPA, the primary efficacy endpoint for this Phase 3 registration trial will be increase in blood pressure. La Jolla plans to initiate this multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial pursuant to the approved SPA in the first quarter of 2015.
LJPC: 18.79 (unch)
La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 04, 7:00AM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 17th Annual BIO CEO & Investor Conference taking place February 9-10 in New York City.
LJPC: 18.79 (unch)
The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 2:34PM CST
GLMD: 6.80 (+0.03), RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
Regado Bio and Tobira to merge
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 8:42AM CST
RPTP: 9.05 (-0.40), GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), RGDO: 1.17 (+0.02)
Galectin up on Phase 1 results in NASH
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 7:50AM CST
GILD: 101.90 (+1.10), LJPC: 18.79 (unch), CNAT: 5.92 (+0.10), SHPG: 239.82 (+6.11), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12)
La Jolla Pharmaceutical (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:19AM CST
La Jolla Pharmaceutical (LJPC) Shares March Higher, Can It Continue?
LJPC: 18.79 (unch)
Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
Business Wire - Mon Dec 29, 1:40PM CST
Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast(TM) (NK-92(TM)), a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D. to the Company's Board of Directors. Mr. Rosen is President of Heron Therapeutics (NASDAQ:HRTX) and Dr. Ji is co-founder, President and CEO of Sorrento Therapeutics, Inc. (NASDAQ:SRNE).
HRTX: 10.29 (+0.39), LJPC: 18.79 (unch), SRNE: 11.41 (+0.56)
Weakness Seen in La Jolla Pharmaceutical (LJPC): Stock Tumbles 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:41AM CST
La Jolla Pharmaceutical aw a big move last session, as the company’s shares fell by nearly 18% which reversed the trend for the company.
LJPC: 18.79 (unch), ARQL: 1.35 (+0.04)
Insider Buys And Sells: American Homes 4 Rent, Western Gas Partners
Asif Suria - at Seeking Alpha - Mon Dec 22, 3:50PM CST
Welcome to edition 235 of Insider Weekends. The prolific buying by insiders of energy companies lost some steam last week even as oil and energy stocks rebounded sharply along with the rest of the market. With the S&P 500 closing less than 5...
RH: 86.77 (-1.55), AMH: 16.58 (-0.10), VRTX: 113.66 (+4.03), CODI: 16.61 (+0.03), RES: 13.36 (+0.93), LJPC: 18.79 (unch), ICE: 233.22 (-1.21), WES: 71.50 (+0.18), ENH: 64.63 (+0.15), GHC: 976.65 (+15.51)
The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 6:37AM CST
LJPC: 18.79 (unch), GALT: 3.84 (+0.16)
La Jolla up on angiotensin IP deal
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:58AM CST
LJPC: 18.79 (unch)
How La Jolla Pharmaceutical (LJPC) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:43AM CST
La Jolla Pharmaceutical is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 72
LJPC: 18.79 (unch)
InsiderInsights.com Daily Round Up 12/15/14: NS, FCX, LJPC, OAS
InsiderInsights - at Seeking Alpha - Tue Dec 16, 2:28AM CST
VR: 42.10 (+0.07), GMCR: 118.53 (+0.56), LJPC: 18.79 (unch), FCX: 20.29 (+0.82), NS: 61.94 (-0.06), OSIS: 71.63 (-0.04), SNI: 73.00 (+0.39), GOOG: 549.01 (+6.08), HAIN: 59.48 (+0.45), WIW: 11.29 (unch), IDRA: 4.10 (-0.14), VRNS: 37.34 (+0.60), WRLD: 78.79 (-0.21), SNPS: 44.90 (+0.03), AI: 25.03 (-0.03), JGW: 10.70 (-0.16), OAS: 16.84 (-0.03), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59)
La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 7.29 (-0.06), LCI: 57.78 (-0.91), LJPC: 18.79 (unch), IG: 10.57 (-0.12)
La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement
Business Wire - Tue Dec 09, 3:01PM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and the George Washington University (GW), today announced that La Jolla and GW have entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. La Jolla plans to initiate a phase 3 registration program of LJPC-501, La Jolla's proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH) in the first quarter of 2015.
LJPC: 18.79 (unch)
LaJolla down on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST
LJPC: 18.79 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 11:48AM CST
IMDZ: 25.34 (+1.20), VTNR: 3.55 (+0.25), CYBR: 52.52 (+6.83), LJPC: 18.79 (unch), ZAZA: 2.17 (+0.08), XPLR: 7.00 (+0.26), FUEL: 14.30 (+0.65), NADL: 2.10 (-0.02), DWA: 20.72 (+0.34), CZR: 10.78 (+0.18), RCAP: 10.28 (+0.28), AMTX: 4.52 (+0.13), FLML: 14.15 (+0.15), AMOT: 22.39 (-0.13), RVNC: 16.84 (+0.27), LOCM: 0.65 (-0.03), JGW: 10.70 (-0.16), ICLD: 2.87 (+0.11), VPCO: 1.02 (+0.01), CSH: 20.53 (-0.31)
La Jolla Pharma -12.5% AH after Q3 report, Phase 2 study results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:00PM CST
LJPC: 18.79 (unch)
La Jolla Pharmaceutical posts 3Q loss
Automated Insights - Wed Nov 12, 4:06PM CST
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Wednesday reported a loss of $5.1 million, or 37 cents per share, in its third quarter.
LJPC: 18.79 (unch)
La Jolla Pharmaceutical misses by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:39PM CST
LJPC: 18.79 (unch)
